Project Details
Description
A Phase 2 Randomized Open Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
| Status | Finished |
|---|---|
| Effective start/end date | 2/1/12 → 1/31/17 |
Funding
- ASTELLAS PHARMA US, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.